GlassScriptPhysician profile
Assad U Darawal
NPI 1902877301
$8,751.01
in general payments reported to CMS, 2019-2025
58 companies · $962 in 2025
The $962 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $1,486 · 2021: $1,514 · 2022: $959 · 2023: $853 · 2024: $1,128 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.22 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $945.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $810.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $721.74 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $658.79 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $564.24 | 2019-2024 | Dificid, Verquvo, Steglatro |
| Allergan, INC. | $423.02 | 2019-2020 | |
| Abbvie INC. | $339.96 | 2019-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $337.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $325.59 | 2019-2024 | Evenity, Prolia, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $238.75 | 2021-2025 | |
| Pfizer INC. | $238.21 | 2019-2025 | |
| Radius Health, INC. | $234.54 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $228.74 | 2021-2025 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $225.84 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.35 | 2019-2025 | Jardiance |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assad Darawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.